Scarica l'app Stockscreener
4.70
4.08%
-0.20
Dopo l'orario di chiusura:
4.66
-0.04
-0.85%
Precedente Chiudi:
$4.90
Aprire:
$4.71
Volume 24 ore:
13,616
Relative Volume:
0.27
Capitalizzazione di mercato:
$10.99M
Reddito:
-
Utile/perdita netta:
$-13.24M
Rapporto P/E:
-0.7036
EPS:
-6.6801
Flusso di cassa netto:
$-12.61M
1 W Prestazione:
-10.31%
1M Prestazione:
-45.29%
6M Prestazione:
-66.88%
1 anno Prestazione:
-73.40%
Intervallo 1D:
$4.54
$4.81
Intervallo di 1 settimana:
$4.21
$5.54
Portata 52W:
$4.21
$17.97
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
4.70 | 10.99M | 0 | -13.24M | -12.61M | -6.6801 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Iniziato | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
Cadrenal Therapeutics, Inc. (CVKD) stock price, news, quote and history - Yahoo Finance UK
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics Announces Warrant Inducement Agreement and Issuance of New Warrants – Form 8-K Filing - Minichart
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement - TipRanks
Cadrenal Therapeutics Raises $2.5 Million via Warrant Exercise, Issues New $4.50 Warrants - TradingView
Warrant exercise gives Cadrenal (NASDAQ: CVKD) $2.5M cash - Stock Titan
Cadrenal Therapeutics (NASDAQ: CVKD) amends warrants; registers 590,001 shares - Stock Titan
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy By Investing.com - Investing.com South Africa
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk - TipRanks
Cadrenal Therapeutics Reports Positive Phase 2 HIT Results and FDA Progress for CAD-1005, Announces Q4 2025 Financials - Minichart
Cadrenal Therapeutics Advances CAD-1005 for HIT Treatment: Clinical Progress, Market Opportunity, and Regulatory Insights - Minichart
Cadrenal Therapeutics 2025 10-K: Net loss $13.24M, EPS $(6.64) - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) pivots to CAD-1005 and expands clotting disorder pipeline - Stock Titan
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy - Investing.com
Cadrenal Therapeutics (NASDAQ: CVKD) widens 2025 loss, advances CAD-1005 toward Phase 3 - Stock Titan
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - marketscreener.com
Drug for rare heparin reaction cut clot events by 25%; FDA maps Phase 3 - Stock Titan
Dividend Watch: Is Cadrenal Therapeutics Inc a strong growth stockFed Meeting & Free Community Supported Trade Ideas - baoquankhu1.vn
Cadrenal Therapeutics, Inc. (CVKD) Eps Diluted (TTM) - Zacks Investment Research
CVKD Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily
Fed Meeting: What is Cadrenal Therapeutics Incs valuation compared to sectorGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Buy Signal: Will Cadrenal Therapeutics Inc outperform its industry peersPortfolio Performance Summary & AI Forecasted Stock Moves - baoquankhu1.vn
OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - tradingview.com
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - Defense World
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial - Investing.com India
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Yahoo Finance
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial By Investing.com - Investing.com Canada
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):